News
HistoIndex Presents Advancements in AI-powered Stain-free Tissue Imaging for NASH Clinical Trials at EASL Congress 2023
SINGAPORE, June 21, 2023 /PRNewswire/ -- HistoIndex today announced that the Company, alongside its collaborators, will present new data on its novel stain-free tissue imaging technology using clinically validated artificial intelligence (AI) algorithms at the EASL Congress, taking place June 21-24, 2023.
Zeta Surgical Announces Successful Treatment of First Patient in Neurosurgical Navigation Clinical Trial at Singapore’s National Neuroscience Institute
SINGAPORE, June 22, 2023 /PRNewswire/ -- Zeta Surgical, a surgical robotics and mixed reality company, has successfully treated its first patient using the Zeta Cranial Navigation System as part of their first-in-human trial at Singapore's National Neuroscience Institute (NNI).
AWAK Technologies and Singapore General Hospital launch pre-pivotal clinical trial of wearable peritoneal dialysis device
SINGAPORE, June 19, 2023 /PRNewswire/ -- AWAK Technologies (AWAK) and Singapore General Hospital (SGH) announce the launch of a pre-pivotal clinical trial with the enrolment of their first subject to study the safety and efficacy of an improved Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device.
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakima in Japan
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
Sun Pharma Announces Health Canada Approval of (PR)WINLEVI® (clascoterone cream 1%) for Topical Treatment of Acne
MUMBAI, India and BRAMPTON, ON, June 19, 2023 /CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715), "Sun Pharma" is pleased to announce Health Canada's approval of PrWINLEVI (clascoterone cream 1%).
Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693
Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it entered into definitive agreements with Qpex Biopharma ("Qpex") and third parties in connection with the acquisition of Qpex by Shionogi.
SK pharmteco doubles viral vector production capacity in Europe
SEOUL, South Korea, June 22, 2023 /PRNewswire/ -- SK pharmteco, SK Inc.'s contract development manufacturing organization (CDMO) for pharmaceuticals, successfully completed its second facility for Cell and Gene Therapies (C>) manufacturing in Europe.
Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023
DAEJEON, South Korea, June 19, 2023 /PRNewswire/ -- Curocell Inc, a Korea-based clinical-stage CAR-T cell therapy company, announced updated Phase 2 interim results for Anbalcabtagene-autoleucel (anbal-cel) on June 15, 2023, at ICML (International Conference on Malignant Lymphoma), Lugano, Switzerland.
SK bioscience COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
SEONGNAM, South Korea, June 19, 2023 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced the company has received the WHO Emergency Use Listing (EUL) of its COVID-19 vaccine, SKYCovione.
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda(TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] as maintenance therapy in adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
